| 词条 | Estradiol valerate/dienogest |
| 释义 |
| image = Estradiol valerate.svg | width = 225px | caption = | image2 = Dienogest.svg | width2 = 250px | caption2 = Estradiol valerate (top) and dienogest (bottom) | type = combo | drug_name = Estradiol valerate / dienogest | component1 = Estradiol valerate | class1 = Estrogen | component2 = Dienogest | class2 = Progestogen | tradename = Natazia, Qlaira | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | routes_of_administration = By mouth | class = Estrogen; Progestogen | CAS_number = | ATC_prefix = | ATC_suffix = | PubChem = | DrugBank = | synonyms = EV/DNG }} Estradiol valerate/dienogest (EV/DNG), sold under the brand names Natazia and Qlaira among others, is a combination product of estradiol valerate, an estrogen, and dienogest, a progestogen, which is used in menopausal hormone therapy in and as a birth control pill to prevent pregnancy in women. It is taken by mouth. Birth control pills containing EV/DNG are associated with a significantly increased risk of venous thromboembolism.[1] However, they are associated with a significantly lower risk of venous thromboembolism than birth control pills containing ethinylestradiol and a progestin.[1] See also
References1. ^1 {{cite journal | vauthors = Fruzzetti F, Cagnacci A | title = Venous thrombosis and hormonal contraception: what's new with estradiol-based hormonal contraceptives? | journal = Open Access J Contracept | volume = 9 | issue = | pages = 75–79 | date = 2018 | pmid = 30519125 | pmc = 6239102 | doi = 10.2147/OAJC.S179673 | url = }} {{Estrogens and antiestrogens}}{{Progestogens and antiprogestogens}}{{Estrogen receptor modulators}}{{Progesterone receptor modulators}}{{Steroid-stub}}{{Genito-urinary-drug-stub}} 1 : Combined estrogen–progestogen formulations |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。